Form 4: Veracyte Director Karin Eastham Sells Shares Under 10b5-1 Plan

Director Karin Eastham sold a total of 14,731 shares of Veracyte stock on November 19, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Karin Eastham, a director at Veracyte, Inc., sold 14,731 shares of common stock on November 19, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 20, 2024.
• The shares were sold in multiple transactions at weighted average prices of $36.7663, $37.7704, and $38.756.
• The total number of shares sold was 1,600 at the first price, 3,006 at the second price, and 10,125 at the third price.
• Following these transactions, Eastham directly owns 18,497 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Risks

• The sale of shares by a director could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. The use of 10b5-1 plans is a legal way for insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for corporate insiders to manage their stock holdings while avoiding accusations of insider trading.
• The reported sales are within the normal range of insider transactions for a company of Veracyte's size and stage.

Stakeholder Impact

• The sale of shares by a director may cause some concern among shareholders, but the use of a 10b5-1 plan mitigates the risk of insider trading.

Key Dates

Keywords

Veracyte, insider trading, Form 4, stock sale, Karin Eastham, Rule 10b5-1, director